Stocklytics Platform
Asset logo for symbol SPRY
Silverback Therapeutics
SPRY56
$11.35arrow_drop_up2.16%$0.24
Asset logo for symbol SPRY
SPRY56

$11.35

arrow_drop_up2.16%

Income Statement (SPRY)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT-$13.19M-$10.22M-$18.01M-$20.62M-$18.73M
EBITDA-$13.18M-$10.21M-$17.99M-$20.60M-$18.71M
gross Profit-$11.00K-$42.00K-$21.00K-$7.29M-$6.53M
NET Income-$10.29M-$7.16M-$14.84M-$17.37M-$11.20M
total Revenue$0.00-$30.00K$0.00$10.00K$20.00K

Balance Sheet (SPRY)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt-$55.78M-$70.69M-$60.20M-$118.63M-$87.43M
stockholders Equity$223.86M$230.76M$237.28M$248.55M$261.15M
total Assets$227.58M$233.18M$248.55M$258.75M$271.19M
total Debt$217.00K$274.00K$327.00K$379.00K$431.00K
total Liabilities$3.71M$2.42M$11.27M$10.20M$10.03M

Cash Flow (SPRY)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow$258.00K$1.80M$921.00K$2.85M$1.31M
free Cash Flow-$6.79M-$17.31M-$12.80M-$16.69M-$12.62M
investing Cash Flow---$44.97M-$111.54M
operating Cash Flow-$6.71M-$17.40M-$12.76M-$16.66M-$12.42M

Silverback Therapeutics (SPRY) Financials

ARS Pharmaceuticals, Inc. (SPRY) provides its financial statements to give investors and stakeholders insights into its financial performance. The income statement presents the company's revenue and expenses over a specific period. It shows the net income from stockholders, which indicates the profitability of the company.

One important financial metric is EBIT (earnings before interest and taxes), which represents the company's operating income before deducting interest and taxes. EBITDA (earnings before interest, taxes, depreciation, and amortization) is also a commonly used metric that provides a clearer picture of a company's profitability by excluding non-cash items such as depreciation and amortization.

Gross profit is another key measure that represents the revenue remaining after subtracting the cost of goods sold. It indicates the profitability of the company's core operations.

The balance sheet displays the company's financial position at a specific point in time, including its assets, liabilities, and stockholders' equity. Cash equivalents refer to highly liquid assets that can be easily converted into cash.

Net debt is calculated by subtracting a company's cash and cash equivalents from its total debt. It indicates the company's ability to meet its financial obligations.

Stockholders' equity represents the residual interest in the assets of the company after deducting liabilities. It reflects shareholders' ownership and indicates the company's net worth.

Total assets and total liabilities are crucial figures on the balance sheet. Total assets include all the resources owned by the company, while total liabilities represent the company's obligations.

Cash flow is a statement that shows the company's cash inflows and outflows during a specified period. It consists of three sections: operating cash flow, investing cash flow, and financing cash flow. These sections provide insights into how the company generates and uses its cash.

Free cash flow represents the cash generated from operations after deducting capital expenditures required to maintain or expand the company's asset base.

In summary, ARS Pharmaceuticals, Inc. (SPRY) releases financial statements to provide a comprehensive view of its financial performance, position, and cash flow.

add Silverback Therapeutics  to watchlist

Keep an eye on Silverback Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics, Inc. All rights reserved.

Stocklytics isn't a brokerage or dealer; it's supported by an affiliated investment adviser for an exchange traded fund. However, this adviser doesn't offer guidance to individual investors. None of the information on Stocklytics suggests buying or selling securities. The site and its newsletters aren't intended as investment advice. It's important to note that past performance isn't indicative of future results. Stocklytics doesn't guarantee the completeness or accuracy of its information. Also, the listed entities aren't affiliated with Stocklytics, LLC. Stock quotes come from InterActive Data, and Morningstar provides daily updated fundamental company data.

Stocklytics Discord public channelStocklytics X Social Media